Category: Blog

Antonov Foundation donates $1M to SRF’s End of Year Campaign

At the end of each year, SRF launches our final fundraising campaign – the aptly named End of Year Campaign – to encourage our donors to donate during the most giving time of year. This year, matching funds from Michael Antonov and a team of other supporters helped you to smash through our original goal.

Read More »

Parabiosis: the Dilution Solution?

In heterochronic parabiosis, joining the circulatory systems of young and old mice causes the older animal to recover some features of youth. The effect has been widely assumed to be driven by pro-youth factors in younger blood, but an alternative hypothesis is possible: that the procedure is instead diluting pro-aging factors in the older partner.

Read More »

Send In The Senolytics

Elie Dolgin’s recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

Read More »

ApoptoSENS team at the SRF Research Center granted a Catalyst award

We are pleased to announce that the ApoptoSENS team led by Dr. Amit Sharma at the SRF Research Center has recently been granted a Catalyst award, courtesy of the Healthy Longevity Global Competition, to continue and expand their critical work on the interactions between senescent cells and natural killer (NK) cells.

Read More »

Tracking Down Glucosepane

The loss of physical function seen in aging tissues is partly due to the formation of irreversible crosslinks between proteins. A new paper in ACS Chemical Biology reports SRF-funded work in the lab of Yale’s Prof. David Spiegel on an antibody that specifically labels the major crosslink glucosepane – a crucial step towards its removal.

Read More »
Latest News

A Letter to the Economist

To the Editors:

Your special report highlighted the growing number of people suffering dementia as one of the many terrible effects of an aging world. It did not consider the potential of medical intervention into aging itself to mitigate that future.

Read More »

First Glimpse of Thymic Rejuvenation

Engineering of new thymus tissue is a key rejuvenation biotechnology, to prevent or reverse the dramatic rise in morbidity and mortality from infectious disease that begins in the seventh decade of life. SENS Research Foundation is supporting thymus engineering research at the Wake Forest Institute of Regenerative medicine. In an important first, researchers at UCSF have derived a simple thymus-like tissue transplant that gave promising signs of restoring the ability to help form mature T-cells.

Read More »

Aging, and the Cure of the Diseases of Aging

We’ve all heard the terminology. “Age-related disease.” “The diseases of aging.” “The diseases of old age.” But what do we mean by them? What is the connection between aging and heart disease, or cancer, or Alzheimer’s? And how is SENS Research Foundation targeting that connection to prevent and cure these diseases?

Read More »

Cell Reprogramming Leaps Ahead: First Transplant of Primate Induced Pluripotent Cell-Derived Neurons into Donor Brain

“Reprogramming” of adult differentiated cells into pluripotent stem cells is an exciting method in biology that holds enormous promise for rejuvenation biotechnology. Now, for the first time, Dr. Su-Chun Zhang and coworkers at the University of Wisconsin-Madison have successfully generated neurons from reprogrammed nonhuman primate cells, transplanted them back into the same animal’s brain, and seen them successfully and cleanly integrate into the local tissue.

Read More »

Project: Break Aging Arteries Free

SENS Research Foundation has established a new research center at Cambridge University and a collaboration with scientists at Yale University. The mission: develop new therapies to repair a critical form of molecular damage that drives the slow stiffening of the arteries with age. Such rejuvenation biotechnologies could prevent such deadly and disabling diseases of aging as stroke and kidney disease.

Read More »

“Accelerated Aging:” Inspiration Beyond Equivocation

The preliminary results of a clinical trial for a disease of “premature aging” – Hutchinson-Gilford Progeria Syndrome (HGPS) – are hopeful and inspiring. However, they cannot directly inform the development of rejuvenation biotechnologies; although the symptoms of HGPS are similar to those observed in aging, there is no evidence to suggest that the underlying mechanism is pathologically significant in those not afflicted with the disease.

Read More »

ShARM: The Miracle of the Loaves and Fishes comes to Aging Research

Aging laboratory rodents are the foundation of our ability to study the degenerative aging process, and develop the rejuvenation biotechnologies that will arrest and reverse it. They’re also expensive, logistically intensive, and in short supply. A new UK initiative has been establish to greatly expand what we can learn from the aging animals in our collective care, and to get a fuller picture of aging and its deceleration and reversal than has hitherto been possible.

Read More »

Tale of Telomerase: Lessons and Limits in a Late-Life Launch

Recent studies show the potential – and the limits – of inducing telomerase expression in aging mice. We place these results in context and explore their implications for new treatments targeting age-related degeneration in humans, particularly examining how telomerase activity relates to the development of cancer.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2025 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can